智通财经APP讯，丽珠医药(01513)发布公告，近日，公司全资子公司丽珠集团利民制药厂收到国家药品监督管理局核准签发的《药品注册证书》(证书编号：2025S00728)，黄体酮注射液获批上市。
黄体酮注射液于2023年4月递交上市申请，受理号为：CYHS2301111。黄体酮注射液的适应症为用于辅助生殖技术(ART)中黄体酮的补充治疗。通过羟丙基倍他环糊精包合技术，将黄体酮制备成水溶性的注射液，可肌肉注射，也可进行皮下注射，不仅规避了传统油性制剂引发的肌肉组织不良反应，还凭借水溶特性加速药物吸收。此外，患者在接受指导后可自行皮下注射，在提升便捷性的同时，降低了附加成本，有效提升了患者的接受度和依从性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.